Global Wealth Management Investment Advisory’s ADMA Biologics ADMA Stock Holding History

Global Wealth Management Investment Advisory’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-500	Closed	-$2.26K	–	142
2023 Q4	$2.26K	Hold	500	–	–	﹤0.01%	392
2023 Q3	$1.79K	Hold	500	–	–	﹤0.01%	386
2023 Q2	$1.84K	Buy	+500	New	+$1.85K	﹤0.01%	394
2022 Q3	–	Sell	-500	Closed	-$1K	–	140
2022 Q2	$1K	Hold	500	–	–	﹤0.01%	442
2022 Q1	$1K	Hold	500	–	–	﹤0.01%	443
2021 Q4	$1K	Hold	500	–	–	﹤0.01%	419
2021 Q3	$1K	Hold	500	–	–	﹤0.01%	437
2021 Q2	$1K	Buy	+500	New	+$880	﹤0.01%	413

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Global Wealth Management Investment Advisory's ADMA Position: Q1 2024 in Review

Global Wealth Management Investment Advisory sold out of ADMA Biologics (ADMA) in Q1 2024, closing a stake of 500 shares — an estimated $2.26K sold.

Global Wealth Management Investment Advisory first reported a position in ADMA in Q2 2021 and held it in 8 quarters. The position peaked at $2.26K in Q4 2023. 214 funds tracked by Wall St. Rank hold ADMA as of Q1 2024.

Global Wealth Management Investment Advisory reported no remaining ADMA Biologics position as of Q1 2024 after selling out during the quarter.
Global Wealth Management Investment Advisory sold 500 ADMA Biologics shares in Q1 2024, an estimated $2.26K.
Global Wealth Management Investment Advisory first reported a position in ADMA Biologics in Q2 2021 and held it in 8 quarters.
Global Wealth Management Investment Advisory's ADMA Biologics position peaked at $2.26K in Q4 2023.
214 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2024.

Based on Global Wealth Management Investment Advisory's 13F filing for Q1 2024, filed 10 May 2024.